Menu

Oncotarget Journal Cut from Medline

New papers from a cancer journal once named as a possibly predatory publication will no longer appear in the widely used research database.

Oct 26, 2017
Katarina Zimmer

ISTOCK, FACTORYTHMedline—a government biomedical research database—no longer lists new research articles from a cancer journal with a troubled reputation. 

Oncotarget, published by Impact Journals, was included in a now-inactive list of “possible predatory publishers” maintained by Jeffrey Beall, a librarian at the University of Colorado Denver. Beall has criticized Oncotarget’s peer review process as “questionable.”  

According to Retraction Watch, Oncotarget has issued “a handful” of recent retractions. This includes a paper published earlier this year on the genetics that underlie the development of cancer that was reportedly pulled due to “data errors” and “negligence.” Retraction Watch reports that the editor-in-chief, Mikhail Blagosklonny, considered retracting the research papers of Beall’s colleagues after the journal had been added to Beall’s list and Beall alerted the journal to potential problems with the publications. 

Medline is maintained by the U.S. National Library of Medicine, which gave no explanation as to why the journal was removed, according to Retraction Watch. However, papers published in Oncotarget will remain available on Pubmed, one of the most popular search tools for biomedical literature.

Beall coined the term predatory publishing to describe journals the exploit the open-access publishing model by collecting fees for publication that are well below those charged by legitimate open-access journals. Beall told The Scientist earlier this year, “They try to trick honest researchers, and sometimes they are successful.” 

Correction (November 15): Oncotarget’s legal representation alerted us to several inaccuracies, which we have clarified. The first paragraph now states that new articles are no longer listed in Medline. The third paragraph clarifies that it was Beall who had alerted Oncotarget to possible problems in his colleagues’ papers, and that Blagosklonny had considered retracting them. The Scientist regrets the errors.

Correction (November 17): The subheading to the article was clarified to also note that only new papers are de-listed from Medline and that Bealls list referred to journals as possibly predatory.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.